Wave Life Sciences (WVE) Files Form 144 for 9,670-Share Sale

Rhea-AI Filing Summary

Wave Life Sciences (WVE) filed a Form 144 disclosing a proposed sale of 9,670 common shares to be executed through J.P. Morgan Securities on Nasdaq with an approximate sale date of 08/13/2025. The filing lists an aggregate market value of $74,459 and notes 159,140,460 shares outstanding, indicating the planned sale represents a very small fraction of the company’s shares. The securities were acquired as Restricted Stock Units from the issuer on 08/12/2025, with payment noted as cash on that date. The filer reports no securities sold in the prior three months and makes the standard representation about lacking undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Small, routine insider sale of RSU-derived shares; unlikely to be material to WVE equity holders.

The Form 144 notifies the market of a proposed sale of 9,670 shares with an aggregate value of $74,459, to occur on 08/13/2025 via J.P. Morgan on Nasdaq. Relative to the reported 159,140,460 shares outstanding, the transaction is negligible in scale and does not indicate a concentration of selling pressure. The filing also notes the shares were acquired as restricted stock units on 08/12/2025 and paid in cash, and that there were no sales in the past three months. Based on these facts alone, the disclosure appears routine and non-material.

Corporate Governance Expert

TL;DR: Proper insider disclosure of intended sale; corporate governance practice upheld by filing.

The filer used Form 144 to disclose an intended sale and included acquisition details (RSU on 08/12/2025) and sale timing (08/13/2025). The filing contains the standard attestation about lack of undisclosed material adverse information. While the document omits some issuer contact fields in the provided extract, the core elements required for market transparency—the amount, value, acquisition type, and planned sale date—are present. This fulfills routine disclosure obligations and supports transparency.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	9670	74459	159140460	08/13/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/12/2025	Restricted Stock Unit	Issuer			9670	08/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Wave Life Sciences (WVE) disclose in the Form 144?

The Form 144 discloses a proposed sale of 9,670 common shares with an aggregate market value of $74,459, to be sold on 08/13/2025 on Nasdaq.

How were the shares WVE plans to sell acquired?

The filing states the shares were acquired as Restricted Stock Units from the issuer on 08/12/2025 and payment was by cash on that date.

How large is the planned sale relative to WVE's outstanding shares?

The filing reports 159,140,460 shares outstanding; the planned sale of 9,670 shares represents a very small fraction of the total share count.

Were there any other sales by this person in the past three months?

The Form 144 indicates "Nothing to Report" under securities sold during the past three months.

Which broker is handling the proposed sale for WVE?

The proposed sale is listed as to be handled by J.P. Morgan Securities LLC, address shown in the filing.